• Something wrong with this record ?

Local control and patient survival after stereotactic radiosurgery for esophageal cancer brain metastases: an international multicenter analysis

O. Bin-Alamer, H. Abou-Al-Shaar, R. Singh, G. Bowden, D. Mathieu, HK. Perlow, JD. Palmer, S. Elhamdani, M. Shepard, Y. Liang, AM. Nabeel, WA. Reda, SR. Tawadros, K. Abdel Karim, AMN. El-Shehaby, R. Emad Eldin, AH. Elazzazi, RE. Warnick, YM....

. 2025 ; 142 (5) : 1357-1365. [pub] 20241206

Language English Country United States

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc25015989

OBJECTIVE: This study aimed to evaluate local control (LC) of tumors, patient overall survival (OS), and the safety of stereotactic radiosurgery (SRS) for esophageal cancer brain metastases (EBMs). METHODS: This retrospective cohort study used data from 15 International Radiosurgery Research Foundation facilities encompassing 67 patients with 185 EBMs managed using SRS between January 2000 and May 2022. The median patient age was 63 years, with a male predominance (92.5%). Most patients (64.2%) had a single brain metastasis, while 7.5% had more than 5 metastases. The median tumor volume was 0.9 cm3, and the median margin dose delivered to the tumor was 20 Gy. RESULTS: The median OS post-SRS was 15.2 months, with 1- and 2-year OS rates of 65.7% and 32.3%, respectively. A significant inverse correlation was found between the number of EBMs and OS in the univariable analysis. LC rates at 1 and 2 years were 89% and 76%, respectively. Adverse radiation effects (AREs) were observed in 17.9% of patients, with 13.4% being mild and transient and 4.5% severely symptomatic (Common Terminology Criteria for Adverse Events grade 3). New intracranial disease developed in 58.2% of patients, with 1- and 2-year rates of 58% and 73%, respectively. CONCLUSIONS: SRS for EBMs demonstrated high survival rates and effective tumor control, with a low incidence of severe AREs. These findings highlight the potential role of SRS in the multidisciplinary multimodality management paradigm of EBM.

Ain Shams University Cairo Egypt

Clinical Oncology Ain Shams University Cairo Egypt

Department of Neurological Surgery University of Pittsburgh Medical Center Pittsburgh Pennsylvania

Department of Neurological Surgery University of Virginia Charlottesville Virginia

Department of Neurosurgery Benha University Benha Egypt

Department of Neurosurgery Humanitas Research Hospital IRCCS Milan Italy

Department of Neurosurgery Koç University School of Medicine Istanbul Turkey

Department of Neurosurgery Neurological Institute Taipei Veterans General Hospital Taipei Taiwan

Department of Neurosurgery Université de Sherbrooke Centre de recherche du CHUS Sherbrooke Québec Canada

Department of Neurosurgery University of Alberta Edmonton Alberta Canada

Department of Neurosurgery University of Pennsylvania Philadelphia Pennsylvania

Department of Neurosurgery Yale University School of Medicine New Haven Connecticut

Department of Radiation Oncology Mayo Clinic Florida Jacksonville Florida

Department of Radiation Oncology National Cancer Institute Cairo University Cairo Egypt

Department of Radiation Oncology Virginia Commonwealth University Health System Richmond Virginia

Department of Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czech Republic

Departments of11Neurosurgery and

Departments of5Radiation Oncology and

Departments of7Neurosurgery and

Gamma Knife Center Jewish Hospital Mayfield Clinic Cincinnati Ohio

Gamma Knife Center Nasser Institute Hospital Cairo Egypt

National Yang Ming Chiao Tung University School of Medicine Hsinchu Taiwan

Neurosurgery The James Cancer Hospital and Solove Research Institute Ohio State University Wexner Medical Center Columbus Ohio

Radiation Oncology Allegheny Health Network Pittsburgh Pennsylvania

Rose Ella Burkhart Brain Tumor and Neuro Oncology Center Neurological Institute Cleveland Clinic Cleveland Ohio

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015989
003      
CZ-PrNML
005      
20250731091421.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.3171/2024.7.JNS24920 $2 doi
035    __
$a (PubMed)39642356
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bin-Alamer, Othman $u 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
245    10
$a Local control and patient survival after stereotactic radiosurgery for esophageal cancer brain metastases: an international multicenter analysis / $c O. Bin-Alamer, H. Abou-Al-Shaar, R. Singh, G. Bowden, D. Mathieu, HK. Perlow, JD. Palmer, S. Elhamdani, M. Shepard, Y. Liang, AM. Nabeel, WA. Reda, SR. Tawadros, K. Abdel Karim, AMN. El-Shehaby, R. Emad Eldin, AH. Elazzazi, RE. Warnick, YM. Gozal, M. Daly, B. McShane, M. Addis-Jackson, G. Karthikeyan, S. Smith, P. Picozzi, A. Franzini, T. Kaisman-Elbaz, HC. Yang, J. Hess, K. Templeton, Z. Wei, S. Pikis, G. Mantziaris, G. Simonova, R. Liscak, S. Peker, Y. Samanci, V. Chiang, CC. Lee, DM. Trifiletti, A. Niranjan, LD. Lunsford, JP. Sheehan
520    9_
$a OBJECTIVE: This study aimed to evaluate local control (LC) of tumors, patient overall survival (OS), and the safety of stereotactic radiosurgery (SRS) for esophageal cancer brain metastases (EBMs). METHODS: This retrospective cohort study used data from 15 International Radiosurgery Research Foundation facilities encompassing 67 patients with 185 EBMs managed using SRS between January 2000 and May 2022. The median patient age was 63 years, with a male predominance (92.5%). Most patients (64.2%) had a single brain metastasis, while 7.5% had more than 5 metastases. The median tumor volume was 0.9 cm3, and the median margin dose delivered to the tumor was 20 Gy. RESULTS: The median OS post-SRS was 15.2 months, with 1- and 2-year OS rates of 65.7% and 32.3%, respectively. A significant inverse correlation was found between the number of EBMs and OS in the univariable analysis. LC rates at 1 and 2 years were 89% and 76%, respectively. Adverse radiation effects (AREs) were observed in 17.9% of patients, with 13.4% being mild and transient and 4.5% severely symptomatic (Common Terminology Criteria for Adverse Events grade 3). New intracranial disease developed in 58.2% of patients, with 1- and 2-year rates of 58% and 73%, respectively. CONCLUSIONS: SRS for EBMs demonstrated high survival rates and effective tumor control, with a low incidence of severe AREs. These findings highlight the potential role of SRS in the multidisciplinary multimodality management paradigm of EBM.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a radiochirurgie $x metody $x škodlivé účinky $7 D016634
650    12
$a nádory jícnu $x patologie $x mortalita $7 D004938
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory mozku $x sekundární $x radioterapie $x mortalita $7 D001932
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a výsledek terapie $7 D016896
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Abou-Al-Shaar, Hussam $u 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
700    1_
$a Singh, Raj $u 2Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, Virginia
700    1_
$a Bowden, Greg $u 3Department of Neurosurgery, University of Alberta, Edmonton, Alberta, Canada
700    1_
$a Mathieu, David $u 4Department of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada
700    1_
$a Perlow, Haley K $u Departments of5Radiation Oncology and
700    1_
$a Palmer, Joshua D $u Departments of5Radiation Oncology and $u 6Neurosurgery, The James Cancer Hospital and Solove Research Institute, Ohio State University Wexner Medical Center, Columbus, Ohio
700    1_
$a Elhamdani, Shahed $u Departments of7Neurosurgery and
700    1_
$a Shepard, Matthew $u Departments of7Neurosurgery and
700    1_
$a Liang, Yun $u 8Radiation Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania
700    1_
$a Nabeel, Ahmed M $u 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt $u 10Department of Neurosurgery, Benha University, Benha, Egypt
700    1_
$a Reda, Wael A $u 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt $u Departments of11Neurosurgery and
700    1_
$a Tawadros, Sameh R $u 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt $u Departments of11Neurosurgery and
700    1_
$a Abdel Karim, Khaled $u 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt $u 12Clinical Oncology, Ain Shams University, Cairo, Egypt
700    1_
$a El-Shehaby, Amr M N $u 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt $u Departments of11Neurosurgery and
700    1_
$a Emad Eldin, Reem $u 9Gamma Knife Center, Nasser Institute Hospital, Cairo, Egypt $u 13Department of Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
700    1_
$a Elazzazi, Ahmed Hesham $u 14Ain Shams University, Cairo, Egypt
700    1_
$a Warnick, Ronald E $u 15Gamma Knife Center, Jewish Hospital, Mayfield Clinic, Cincinnati, Ohio
700    1_
$a Gozal, Yair M $u 15Gamma Knife Center, Jewish Hospital, Mayfield Clinic, Cincinnati, Ohio
700    1_
$a Daly, Megan $u 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania
700    1_
$a McShane, Brendan $u 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania
700    1_
$a Addis-Jackson, Marcel $u 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania
700    1_
$a Karthikeyan, Gokul $u 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania
700    1_
$a Smith, Sian $u 16Department of Neurosurgery, University of Pennsylvania, Philadelphia, Pennsylvania
700    1_
$a Picozzi, Piero $u 17Department of Neurosurgery, Humanitas Research Hospital - IRCCS, Milan, Italy
700    1_
$a Franzini, Andrea $u 17Department of Neurosurgery, Humanitas Research Hospital - IRCCS, Milan, Italy
700    1_
$a Kaisman-Elbaz, Tehila $u 18Rose Ella Burkhart Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
700    1_
$a Yang, Huai-Che $u 19Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan $u 20National Yang Ming Chiao Tung University School of Medicine, Hsinchu, Taiwan
700    1_
$a Hess, Judith $u 21Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut
700    1_
$a Templeton, Kelsey $u 21Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut
700    1_
$a Wei, Zhishuo $u 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
700    1_
$a Pikis, Stylianos $u 22Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
700    1_
$a Mantziaris, Georgios $u 22Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
700    1_
$a Simonova, Gabriela $u 23Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Liscak, Roman $u 23Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Peker, Selcuk $u 24Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey; and
700    1_
$a Samanci, Yavuz $u 24Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey; and
700    1_
$a Chiang, Veronica $u 21Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut
700    1_
$a Lee, Cheng-Chia $u 19Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan $u 20National Yang Ming Chiao Tung University School of Medicine, Hsinchu, Taiwan
700    1_
$a Trifiletti, Daniel M $u 25Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, Florida
700    1_
$a Niranjan, Ajay $u 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
700    1_
$a Lunsford, L Dade $u 1Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
700    1_
$a Sheehan, Jason P $u 22Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia
773    0_
$w MED00002843 $t Journal of neurosurgery $x 1933-0693 $g Roč. 142, č. 5 (2025), s. 1357-1365
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39642356 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091416 $b ABA008
999    __
$a ok $b bmc $g 2366680 $s 1253114
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 142 $c 5 $d 1357-1365 $e 20241206 $i 1933-0693 $m Journal of neurosurgery $n J Neurosurg $x MED00002843
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options